<DOC>
	<DOCNO>NCT00174642</DOCNO>
	<brief_summary>Primary objective : - To show non inferiority term efficacy ( HbA1c ) insulin glargine plus metformin combine 1 3 bolus insulin glulisine introduce progressively ( Arm 2 ) compare insulin glargine plus metformin combine 3 bolus insulin glulisine ( Arm 1 ) , type 2 diabetes mellitus patient poorly control basal insulin therapy oral antidiabetic drug . - To show non inferiority term efficacy ( HbA1c ) insulin glargine plus metformin combine 1 3 bolus insulin glulisine introduce progressively ( Arm 2 ) compare insulin glargine plus metformin insulin secretagogue ( sulfonylurea glinide ) combine 1 3 bolus insulin glulisine introduce progressively ( Arm 3 ) , type 2 diabetes mellitus patient poorly control basal insulin therapy oral antidiabetic drug . Secondary objective : - To compare 3 treatment group : evolution HbA1c time , percentage subject HbA1c &lt; = 7 % end study , evolution blood glucose profile , incidence hypoglycemia , insulin dos , evolution body weight treatment satisfaction .</brief_summary>
	<brief_title>Opposing Step-by-step Insulin Reinforcement Intensified Strategy</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin glulisine</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Inclusion criterion : Type 2 diabetic BMI ≤ 40 kg/m² HbA1c &gt; 7 % Treated basal insulin ( NPH , Insulin Zinc , insulin glargine insulin detemir ) , least , two OAD include insulin secretagogue ( sulfonylurea glinide , dosage ) metformin ( maximum tolerate dosage ) , 6 month Exclusion criterion : Type 1 diabetes mellitus Treatment OADs Treatment thiazolidinediones Treatment insulin basal insulin ( Premix , rapid insulin , fastacting insulin analogue ) Active proliferative diabetic retinopathy , define application photocoagulation surgery , 6 month study entry unstable ( rapidly progress ) retinopathy may require photocoagulation surgery study ( confirm optic fundus perform 2 year prior study entry ) Pregnancy ( woman childbearing potential must negative pregnancy test study entry effective contraception ) Breastfeeding History hypersensitivity study drug drug similar chemical structure insulin glargine Treatment systemic corticosteroid , irrespective dose administration irrespective prior foreseeable treatment duration Treatment investigational product last 2 month study entry , except insulin glargine Likelihood require treatment study period drug permit clinical study protocol Clinically relevant cardiovascular , hepatic , neurological , endocrine , major disease make implementation protocol interpretation study result difficult Impaired hepatic function show ALT and/or AST great three time upper limit normal study entry Impaired renal function show serum creatinine &gt; 135 μmol/l men &gt; 110 μmol/l woman study entry History drug alcohol abuse Mental condition render subject unable understand nature , scope possible consequence study Subject unlikely comply protocol , e.g. , uncooperative attitude , inability return followup visit , unlikelihood complete study Subject deprive freedom judicial administrative decision Subject investigator subinvestigator , research assistant , pharmacist , study coordinator , staff relative thereof directly involve conduct protocol . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>